Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation

Recombinant human thrombopoietin (rHuTPO) is a drug that is used clinically to promote megakaryocyte and platelet generation. Here, we report the mitigative effect of rHuTPO (administered after exposure) against severe whole body irradiation in mice. Injection of rHuTPO for 14 consecutive days follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chao, Zhang, Bowen, Wang, Sihan, Zhang, Jing, Liu, Yiming, Wang, Jingxue, Fan, Zeng, Lv, Yang, Zhang, Xiuyuan, He, Lijuan, Chen, Lin, Xia, Huanzhang, Li, Yanhua, Pei, Xuetao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585893/
https://www.ncbi.nlm.nih.gov/pubmed/26403418
http://dx.doi.org/10.1038/srep12993
Descripción
Sumario:Recombinant human thrombopoietin (rHuTPO) is a drug that is used clinically to promote megakaryocyte and platelet generation. Here, we report the mitigative effect of rHuTPO (administered after exposure) against severe whole body irradiation in mice. Injection of rHuTPO for 14 consecutive days following exposure significantly improved the survival rate of lethally irradiated mice. RHuTPO treatment notably increased bone marrow cell density and LSK cell numbers in the mice after sub-lethal irradiation primarily by promoting residual HSC proliferation. In lethally irradiated mice with hematopoietic cell transplantation, rHuTPO treatment increased the survival rate and enhanced hematopoietic cell engraftment compared with the placebo treatment. Our observations indicate that recombinant human TPO might have a therapeutic role in promoting hematopoietic reconstitution and HSC engraftment.

Ejemplares similares